Idiopathic Intracranial Hypertension Treatment Trial



Status:Completed
Conditions:High Blood Pressure (Hypertension), Neurology
Therapuetic Areas:Cardiology / Vascular Diseases, Neurology
Healthy:No
Age Range:18 - 60
Updated:12/14/2018
Start Date:January 2010
End Date:January 2014

Use our guide to learn which trials are right for you!

A Multicenter, Double-blind, Randomized, Placebo-controlled Study of Weight-Reduction and/or Low Sodium Diet Plus Acetazolamide vs Diet Plus Placebo in Subjects With Idiopathic Intracranial Hypertension With Mild Visual Loss

Idiopathic intracranial hypertension (IIH), also called pseudotumor cerebri, is a disorder of
elevated intracranial pressure of unknown cause [Corbett, et al., 1982; Wall, et al., 1991].
Its incidence is 22.5 new cases each year per 100,000 overweight women of childbearing age,
and is rising [Garrett, et al., 2004] in parallel with the obesity epidemic. It affects about
100,000 Americans. Most patients suffer debilitating headaches. Because of pressure on the
optic nerve (papilledema), 86% have some degree of permanent visual loss and 10% develop
severe visual loss [Wall, et al., 1991]. Interventions to prevent loss of sight, all with
unproven efficacy, include diet, diuretics such as acetazolamide, repeated spinal taps, optic
nerve sheath fenestration surgery, and cerebrospinal fluid (CSF) shunting procedures. The
purported goal of these therapies is to lower intracranial pressure; however, it is unclear
which treatments work and by what mechanism. None of these strategies has been verified by
properly designed clinical trials. Thus, there is confusion, uncertainty, and weak scientific
rationales to guide treatment decisions. This trial will study subjects who have mild visual
loss from IIH to (1) establish convincing, evidence-based treatment strategies for IIH to
restore and protect vision, (2) follow subjects up to 4 years to observe the long-term
treatment outcomes and (3) determine the cause of IIH. To meet those aims, the trial will be
divided into a 12-month intervention phase and a 3-year observational phase. Subjects are not
required to complete the observational phase of the study, but will be asked to do so and
consented for the observational phase of the study at the conclusion of the intervention
phase (12 months).

Clinical Phase: Phase II Investigators: NORDIC Network sites Study Centers: 38 study centers
Coordinating Center - University of Rochester Statistical Center - University of Rochester
Study Period Planned enrollment duration: 2 years Planned duration of treatment: 6 months
followed by open-label treatment Planned duration of follow-up: 4.5 years Study Objectives:
The primary objective is determining the efficacy of diet plus acetazolamide vs diet alone in
reducing or reversing visual loss in subjects with mild visual loss.

The secondary objective is to identify proteomic and genetic risk factors for IIH by
screening a large cohort of IIH patients and controls.

Study Population This project will enroll 166 individuals with IIH who are 18-60 years of
age. We anticipate that the population will be primarily composed of women in the
childbearing years that are overweight. 154 control subjects will also be enrolled. Control
subjects will be matched as closely as possibly by age, sex, race, ethnicity and weight to
subjects enrolled at the site.

Study Design: Multi-center, double-blind randomized intervention study followed by a 4-year
observation period. Subjects will be randomized to diet and acetazolamide or diet and
placebo. The study will use 250 mg acetazolamide or matching placebo tablets taken with food
at meals and at bedtime. The subject will begin with one tablet four times daily, at meals
and at bedtime for the first week. Beginning on Day 7, subjects will increase the dosage by 1
tablet every 4 days until a final dosage of 4 tablets four times daily (4 grams) is reached
or side effects prohibit increasing the dosage further. If the study drug is not tolerated at
a dose of 250 mg, then 125 mg (1/2 tablet) will be tried. If this is not tolerated, no
pharmacologic treatment will be given.

After the 6 month visit, all subjects will transition from study medication to acetazolamide
(open label) by replacing one tablet of study drug with 250 mg of acetazolamide every four
days. The acetazolamide dose will be titrated in a manner similar to the initial study drug
schedule to the maximum tolerated dose of acetazolamide. To avoid treating subjects (who may
have initially been assigned to placebo) unnecessarily, any subject with grade 0-1
papilledema will be tapered off study drug but not placed on acetazolamide unless they have
persisting headaches or pulse-synchronous tinnitus. If so, they will be placed on
acetazolamide regardless of the low papilledema grade. At the 9-month follow-up visit, we
will make sure that the subjects' vision is stable after the transition off of study
medication. After the 9 month visit, medication will be prescribed by the subject's treating
physician. The intervention phase of the study will end at the subject's 12 month visit and
subjects will be invited to participate in the observational phase of the study and consented
to do so if willing.

Number of Subjects: 166 subjects with IIH and 154 control subjects Main Inclusion Criteria

1. Diagnosis of IIH by modified Dandy criteria

2. Diagnosis of IIH for 6 weeks or less

3. Age 18 to 60 years at time of diagnosis

4. Reproducible visual loss present on automated perimetry (in eye with greatest loss)*

5. perimetric mean deviation (PMD) -2 decibel (dB) up to -5 dB in the worst eye

6. Presence of bilateral papilledema

7. Able to provide informed consent or parental permission with appropriate assent

Main Exclusion Criteria

1. Total treatment of IIH of more than one week in the past six weeks

2. Corticosteroids or surgery used for IIH treatment within the past two months

3. Abnormalities on neurologic examination aside from papilledema and its related visual
loss or VI nerve paresis (unless pre-existing and unrelated to IIH)

4. Abnormal CT or MRI scan (intracranial mass, hydrocephalus, dural sinus thrombus or
arteriovenous malformation) other than empty sella, dilated optic nerve sheath,
flattened sclera, or secondary Chiari

5. CSF pressure less than 200 mm water (patients may have repeat CSF pressure measurements
if the first is normal or no opening pressure obtained)

6. Abnormal CSF contents (increased cells, elevated protein, low glucose)

7. Intraocular pressure currently > 28 mm Hg or > 30 mm Hg at any time in the past

8. Refractive error > +/- 6.00 sphere or > +/- 3.00 cylinder in either eye

9. Other disorders causing visual loss except for refractive error and amblyopia including
cells in the vitreous or iritis

10. Inability to provide reliable and reproducible visual field examination (failure to
maintain fixation using an eye monitoring device, more than 15% false positive errors

11. Abnormal blood work-up indicating a medical or systemic condition associated with raised
intracranial pressure (ICP)

12. Exposure to a drug, substance or disorder that has been associated with elevation of
intracranial pressure within 2 months of diagnosis such as lithium, vitamin A,
tetracycline, steroid withdrawal (see table in Manual of Procedures (MOP) for conditions
and drugs)

13. Other condition requiring diuretics, steroids or other pressure lowering agents
including topiramate

14. Presence of a medical condition such as renal stones that would contraindicate use of
the study drugs (acetazolamide)

15. Pregnancy or unwillingness for subject with childbearing potential to use contraception
during the first year of the study

16. Presence of a physical, mental, or social condition likely to affect follow-up (drug
addiction, terminal illness, no telephone, homeless)

17. Anticipation of a move from the site area within six months and unwillingness to return
for follow-up.

Route and Dosage Form: 250 mg acetazolamide tablets or matching placebo taken with food 4
times daily. Subjects will titrate to a maximum dose of 4 tablets 4 times daily (4 grams) as
tolerated. If a subject is not able to tolerate a dose of 250 mg, 125 mg (1/2 tablet) may be
tried. If this is not tolerated, no pharmacologic treatment will be given.

Duration of Treatment: 6 months of randomized treatment followed by open label acetazolamide
treatment. After the 9-month visit medication will be prescribed by the subject's treating
physician. The intervention phase of the study will end at Month 12 and the subject invited
to continue in the observational phase.

Primary Outcome Measure(s): The primary outcome measure is the change from baseline to Month
6 in PMD (perimetric mean deviation) in the eye with the most severe initial visual loss.

Secondary Outcome Measure: CSF pressure measurement by lumbar puncture Number of abnormal
perimetry test locations Visual field examination ratings (improved, remained the same, or
worsened) Papilledema grade QOL assessments Dietary Outcomes (BMI, Waist circumference,
urinary sodium) Safety Outcomes: Adverse events will be tabulated by treatment group,
severity, and perceived relationship to the study intervention Sample Size Considerations

Inclusion Criteria:

1. Diagnosis of IIH by modified Dandy criteria Signs and symptoms of increased
intracranial pressure Absence of localizing findings on neurologic examination Absence
of deformity, displacement, or obstruction of the ventricular system and otherwise
normal neurodiagnostic studies, except for evidence of increased cerebrospinal fluid
pressure (>200 mm water). Abnormal neuroimaging except for empty sella turcica, optic
nerve sheath enlargement, and smooth-walled non flow-related venous sinus stenosis or
collapse106 should lead to another diagnosis Awake and alert No other cause of
increased intracranial pressure present

2. Diagnosis of IIH for 6 weeks or less

3. Age 18 to 60 years at time of diagnosis

4. Reproducible visual loss present on automated perimetry (in eye with greatest loss)

5. Average PMD -2 dB up to -5 dB in the worst eye

6. Presence of bilateral papilledema

7. Able to provide informed consent

8. Women of child-bearing potential must use an acceptable form of birth control during
the intervention phase of the study. Acceptable forms include oral contraceptives,
transdermal contraceptives,

Exclusion Criteria:

1. Total treatment of IIH of more than two weeks (except for acetazolamide which is
limited to 1 week). For every day on treatment there must be a one-day washout period.

2. Previous surgery for IIH including optic nerve sheath fenestration, CSF shunting
procedures, subtemporal decompression and venous stenting

3. Previous gastric bypass surgery

4. Abnormalities on neurologic examination aside from papilledema and its related visual
loss or VI nerve paresis

5. Abnormal CT or MRI scan (intracranial mass, hydrocephalus, dural sinus thrombus or
arteriovenous malformation) other than empty sella, unfolded optic nerve sheaths,
flattened sclera, or smooth- walled venous stenosis

6. CSF pressure less than 200 mm water (patients may have repeat CSF pressure
measurements if the first is normal or no opening pressure obtained)

7. Abnormal CSF contents: increased cells: > 5 cells, elevated protein:

> 45 mg%, low glucose: < 30 mg% (If the lumbar puncture produces a cell count compatible
with a traumatic needle insertion, the patient does not need to be excluded if the CSF WBC
after correction is 5 wbc/mm3 or less- see Operations Manual for calculation) 8.
Intraocular pressure currently > 28 mm Hg or > 30 mm Hg at any time in the past 9.
Refractive error > +/- 6.00 sphere or > +/- 3.00 cylinder in either eye with the following
exceptions: Subjects with myopia of >-6.00 D sphere but less than or equal to - 8.00 D
sphere are eligible if 1)there are no abnormalities on ophthalmoscopy or fundus photos
related to myopia that are associated with visual loss (such as staphyloma, retinal
thinning in the posterior pole or more than mild optic disc tilt), and 2) the subject wears
a contact lens for all perimetry examinations with the appropriate correction. If either
the Site Investigator or the PRC director (or his designate) decides there are optic fundus
abnormalities of myopia that are associated with visual loss, then 9. Subjects with
hyperopia of > +6.00 D but less than or equal to

- 8.00 D sphere are eligible if 1) there is an unambiguous characteristic halo of
peripapillary edema as opposed to features of a small crowded disc or other hyperopic
change related to visual loss determined by the site investigator or the PRC director
(or his designate) and 2) the subject wears a contact le 10. Other disorders causing
visual loss except for refractive error and amblyopia including cells in the vitreous
or iritis 11. Optic disc drusen on exam or in previous history 12. Presence of
diagnosed untreated obstructive sleep apnea 13. Inability to provide reliable and
reproducible visual field examination (failure to maintain fixation using an eye
monitoring device, more than 15% false positive errors) 14. Abnormal blood work-up
indicating a medical or systemic condition associated with raised ICP 15. Study blood
results showing severe anemia, leukopenia or thrombocytopenia, renal failure, or
hepatic disease, based on the Site Investigator's judgment 16. Type I diabetes or the
presence of diabetic retinopathy 17. Exposure to a drug, substance or disorder that
has been associated with elevation of intracranial pressure within 2 months of
diagnosis such as lithium, vitamin A, various cyclines (see table in Operations Manual
for conditions and drugs) 18. Other condition requiring diuretics, oral, I.V. or
injectable steroids or other pressure lowering agents including topiramate (nasal,
inhaled, or topical steroids are allowed since the systemic effects are small) 19.
Presence of a medical condition such as renal stones that would contraindicate use of
the study drug (acetazolamide) 20. Pregnancy or unwillingness for subject of
childbearing potential to use contraception during the first year of the study 21.
Breastfeeding mothers are excluded from participation unless willing to discontinue
breastfeeding by the baseline visit 22. Presence of a physical, mental, or social
condition likely to affect follow-up (drug addiction, terminal illness, no telephone,
homeless) 23. Anticipation of a move from the site area within six months and
unwillingness to return for follow-up at an IIHTT study site 24. Allergy to pupil
dilating drops or narrow angles precluding safe dilation
We found this trial at
40
sites
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
(612) 625-5000
Univ of Minnesota With a flagship campus in the heart of the Twin Cities, and...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
1 Gustave L Levy Pl # 271
New York, New York 10029
 (212) 241-6500
Mount Sinai Med Ctr Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care...
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Bethesda, Maryland 20814
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
2500 University Drive Northwest
Calgary, Alberta T2N 1N4
?
mi
from
Calgary,
Click here to add this to my saved trials
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
281 W. Lane Ave
Columbus, Ohio 43210
(614) 292-6446
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Durham, North Carolina 27710
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
East Lansing, MI
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Lexington, Kentucky
859) 257-9000
University of Kentucky The University of Kentucky is a public, land grant university dedicated to...
?
mi
from
Lexington, KY
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
New York, New York 10021
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Newark, NJ
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73104
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Peoria, Illinois 61656
?
mi
from
Peoria, IL
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Portland, OR
Click here to add this to my saved trials
Raleigh, North Carolina 27607
?
mi
from
Raleigh, NC
Click here to add this to my saved trials
?
mi
from
Rochester, NY
Click here to add this to my saved trials
?
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Saint Louis, Missouri 63104
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Antonio, Texas 78229
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
5300 Tallman Ave NW
Seattle, Washington 98122
(206) 782-2700
Swedish Medical Center Since 1910, Swedish has been the region's hallmark for excellence in health...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Stony Brook, New York 11794
?
mi
from
Stony Brook, NY
Click here to add this to my saved trials
?
mi
from
Syracuse, NY
Click here to add this to my saved trials
?
mi
from
Tallahassee, FL
Click here to add this to my saved trials
Waterbury, Connecticut 06708
?
mi
from
Waterbury, CT
Click here to add this to my saved trials
Winston-Salem, North Carolina 27157
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials